Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633096 | 0.91 | FGFR1 (0.37) | ERBB2HDAC8GSK3BDYRK1AFGFR1 | |
| SCHEMBL19637502 | 0.87 | ERBB2 (0.42) | ERBB2HDAC1HDAC2HDAC8FGFR1 | |
| SCHEMBL19633089 | 0.85 | ERBB2 (0.43) | ERBB2HDAC1HDAC2HDAC8 | |
| SCHEMBL19632860 | 0.83 | ERBB2 (0.42) | ERBB2HDAC1HDAC2HDAC8 | |
| SCHEMBL19636934 | 0.83 | ERBB2 (0.41) | ERBB2HDAC1HDAC2HDAC8 | |
| SCHEMBL19636845 | 0.82 | ERBB2 (0.40) | ERBB2HDAC1HDAC2HDAC8 | |
| SCHEMBL30046311 | 0.79 | SMN1; SMN2 (0.37) | ERBB2HDAC1HDAC2HDAC8 | |
| SCHEMBL30944502 | 0.79 | NAMPT (0.42) | — | |
| SCHEMBL30944532 | 0.79 | NAMPT (0.42) | — | |
| SCHEMBL19614875 | 0.78 | FGFR1 (0.39) | ERBB2FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ERBB2 65/4885HDAC1 1672/4885HDAC2 1196/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ERBB2 65/4885HDAC1 1672/4885HDAC2 1196/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | ERBB2 65/4885HDAC1 1672/4885HDAC2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.